Skip to main content

Table 2 Responses

From: Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer

 

Results

N

%

CNS

N = 22

Complete Response

0

0

Partial Response

2

9

 Parenchymal

0

0

 Leptomeningeal

2

9

Stable Disease

10

45

 Parenchymal

7

32

 Leptomeningeal

1

5

 Parenchymal + leptomeningeal

2

9

Disease control (partial response + stable disease)

12

55

Progression Disease

10

45

 Parenchymal

7

32

 Leptomeningeal

1

5

 Parenchymal + leptomingeal

2

9

Other sites

N = 18

Complete Response

0

0

Partial Response

0

0

Stable Disease

7

39

Progression Disease

11

61